ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Market cap

<< Previous

Bullboard Posts

Next >>

Comment by bball67on May 13, 2022 8:30am

139 Views

Post# 34680764

RE:Market cap

Nobody has stole my shares or my money. I haven't sold any shares. How did they steal yours? Market Cap of $35M US less $17M cash on hand= $18M net Market Cap. Really??? Way undervalued. Read the first quarter press release this morning, Wow there are so many positives, and the forward direction seems very focused.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks